000			01204 a2200337 4500
005			20250515021513.0
264		0	_c20060502
008			200605s 0 0 eng d
022			_a1424-6074
040			_aNLM _beng _cNLM
100	1		_aBradley, R
245	0	0	_aTSE risk assessment for starting materials used during, or in the manufacture of vaccines for human use--a consultant's view of the commercial approach. _h[electronic resource]
260			_bDevelopments in biologicals _c2006
300			_a335-45; discussion 349-54 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aCattle
650	0	4	_aCell Culture Techniques _xstandards
650	0	4	_aCell Line
650	0	4	_aEncephalopathy, Bovine Spongiform _xtransmission
650	0	4	_aHumans
650	0	4	_aPrion Diseases _xepidemiology
650	0	4	_aPrions _xisolation & purification
650	0	4	_aRisk Assessment
650	0	4	_aSafety
650	0	4	_aSheep
650	0	4	_aTissue Banks _xstandards
650	0	4	_aUnited Kingdom
650	0	4	_aVaccines _xstandards
773	0		_tDevelopments in biologicals _gvol. 123 _gp. 335-45; discussion 349-54
999			_c16173837 _d16173837